chrisvoncsefalvay/vaers-outcomes huggingface dataset:
The store was dirty, covid vaccine kept on desks; The store was dirty, covid vaccine kept on desks; had huge infection at the site; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) for a Pfizer sponsored program. The reporter is the patient.  A patient (no qualifiers provided) received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose number unknown, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: PRODUCT STORAGE ERROR (non-serious), POOR QUALITY PRODUCT ADMINISTERED (non-serious), outcome "unknown" and all described as "The store was dirty, covid vaccine kept on desks"; VACCINATION SITE INFECTION (non-serious), outcome "unknown", described as "had huge infection at the site".  Additional information: Customer Verbatim: Just receive Pfizer vaccine at (with held) and had huge infection at the site. The store was dirty, covid vaccine kept on desks.   The lot number for bnt162b2 was not provided and will be requested during follow up.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202101781361 same reporter, different patients/similar events
Member received COVID-19 booster on 6/17/2022, apparently had received booster already at outside pharmacy 5/17/2022. Next day developed urticaria on bilateral upper arms that has persisted until today 7/29/2022, unrelieved with topical hydrocortisone. Has not tried oral antihistamine or oral steroid. She is without s/s angioedema. Rash isolated to arms.
Patient with basil artery occlusion approximately 1 day after receiving  COVID vaccine dose #2.
Pain in the right arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Pain in the right arm) in a 34-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Penicillin allergy and Latex allergy.    On 24-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-May-2021, the patient experienced PAIN IN EXTREMITY (Pain in the right arm). At the time of the report, PAIN IN EXTREMITY (Pain in the right arm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant medications included natural drops for sleeping.  The treatment information was not provided.   Most recent FOLLOW-UP information incorporated above includes: On 27-May-2021: The follow-up was received on 9-JUN-2021 and has no new information.
Feeling light headed, dizzy, vertigo symptoms daily started 2 days after 2nd dose
Collar bone little inflamed; Pain in underarm; Diarrhoea; Headache; Nausea; Fatigue; This spontaneous case was reported by a consumer and describes the occurrence of OSTEITIS (Collar bone little inflamed), AXILLARY PAIN (Pain in underarm), DIARRHOEA (Diarrhoea), HEADACHE (Headache) and NAUSEA (Nausea) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 14-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 15-Apr-2021, the patient experienced OSTEITIS (Collar bone little inflamed), AXILLARY PAIN (Pain in underarm), DIARRHOEA (Diarrhoea), HEADACHE (Headache), NAUSEA (Nausea) and FATIGUE (Fatigue). The patient was treated with IBUPROFEN (ADVIL [IBUPROFEN]) at an unspecified dose and frequency. On 25-Apr-2021, OSTEITIS (Collar bone little inflamed), AXILLARY PAIN (Pain in underarm), DIARRHOEA (Diarrhoea), HEADACHE (Headache), NAUSEA (Nausea) and FATIGUE (Fatigue) had resolved.            Concomitant product use was not provided by the reporter. Treatment for the event included clear broths.
No adverse effect reported; improperly stored V AQTA had been administered; This spontaneous report was received from a nurse referring to a patient of unknown age and gender. The patient's concomitant medications, pertinent medical history and drug reactions/ allergies were not provided.          On 28-OCT-2019, the patient was vaccinated with one dose hepatitis a vaccine, inactivated (VAQTA) (lot number S002506 and expiration date 04-APR-2020; dose number, frequency, anatomical location and route of administration were unknown) for prophylaxis (product storage error). No adverse events were reported. No product quality complaint (PQC) was involved. Temperature and time frame were 46.7 degrees Fahrenheit  for 15 minutes.The call was because of a "data logger''. There was no previous temperature excursion.
strange buzzing, vibrating feeling in her chest; A spontaneous report was received from a consumer concerning herself, a 53 years old female patient who received Moderna's COVID-19 vaccine and experienced strange buzzing, vibrating feeling in her chest/chest discomfort.  The patient's medical history was not provided. Concomitant product use was not provided by the reporter.  On 26-Jan-2021, prior to the onset of the symptoms, the patient received first of two planned doses of mRNA-1273 (batch number unknown) via unknown route for COVID-19 infection prophylaxis.  On 26-Jan-2021, the patient received her first dose of the vaccine. On 28-Jan-2021, patient experienced strange buzzing, vibrating feeling in her chest which is not painful. Treatment information was not provided.  Action taken with mRNA-1273 in response to the event is not reported.  The outcome of the event strange buzzing, vibrating feeling in her chest was unknown.; Sender's Comments: Very limited information regarding this events has been provided at this time. Further information has been requested. Company assessed the events to be unlikely related to company product.
she felt the vaccine go down the arm and had numbness and tingling in hands in the  hand and fingers; she felt the vaccine go down the arm and had numbness and tingling in hands in the  hand and fingers; she felt the vaccine go down the arm and had numbness and tingling in hands in the  hand and fingers; hand turned red; This is a spontaneous report from a contactable consumer or other non hcp (patient). A 37-year-old female patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE solution for injection,Batch/Lot Number: ER8730), via an unspecified route of administration, administered in right arm on 30Mar2021 11:00 (at age of 37-year-old) as dose 1, single for covid-19 immunization. Medical history included asthma from an unknown date and unknown if ongoing. The patient's concomitant medications were not reported. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. No previous immunization with the Pfizer vaccine considered as suspect.She had a small reaction with the Whooping Cough vaccine once, She does not have any vaccine information since its been years and years ago. No additional vaccines administered on same date of the pfizer suspect.On 30Mar2021, immediately after receiving vaccine the patient experienced to feel the vaccine go down the arm and had numbness and tingling in hands in the hand and fingers and patient hand turned red. The patient received Benadryl as a treatment for the events.She wants to know if it is a normal reaction and should she get a second one or not because she had the reaction and she was worried about getting COVID with my asthma.The patient did not visit to emergency room. The outcome of the events was recovered on 30Mar2021.  No follow-up attempts are needed. No further information is expected.
Patient experienced burning rash on stomach and thighs. Patient received a dose of steroid treatment at her doctor's office.
First two days after vaccine - muscle aches and joint paint throughout body; these symptoms subsided by day 3  First 3 days after vaccine - pain and swelling in the lymph nodes under armpit near vaccine. Pain and swelling still present.
After the second dose I am experiencing back pain; This is a spontaneous report received from a non-contactable reporter(s) (Other HCP). The reporter is the patient.  A 30 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), intramuscular, administered in arm left, administration date 20Sep2021 10:30 (Batch/Lot number: unknown) at the age of 30 years as dose 2, single for covid-19 immunisation. The patient's relevant medical history was not reported. There were no concomitant medications. Vaccination history included: Bnt162b2 (Pfizer COVID 19 vaccine, lot_unknown, administrator route: Intramuscular, administration date: 30/Aug/2021, administration time: 10:00 AM, dose number: 1, vaccine location: Left arm), administration date: 30Aug2021, when the patient was 30 years old, for Covid-19 Immunization, reaction(s): "more numbing arms when I sleep". The following information was reported: BACK PAIN (non-serious) with onset 20Sep2021 22:45, outcome "recovering", described as "After the second dose I am experiencing back pain". Therapeutic measures were not taken as a result of back pain.  Additional information: Patient noticed more numbing arms when he sleep and the first dose. After the second dose he was experiencing back pain. Prior to vaccination, patient was not diagnosed with COVID-19, Since the vaccination, the patient was not tested for COVID-19, patient did not received any other vaccines within 4 weeks prior to the COVID vaccine, patient was not received any other medications within 2 weeks of vaccination.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
From telephone correspondence received at a manufacturer on 5/10/02, it was reported that a 62 y.o. male received Imovax and Imogam on 4/11/02 after a bat exposure. After the first dose, PT's left hand pinky and index fingers felt sore and this soreness persisted through entire series and is still present. No problems after 2nd dose. 3rd dose Imovax given on 4/18/02. 3 hours later, PT felt tired, slight photophobia and slight dizziness. PT experienced muscle pain in both arms after received fourth dose on 4/25/02. PT received 5th dose on 5/9/02. Approximately 3 hrs later, PT developed significant aching in hips and both arms, fingers hurt when extended, also experienced shaking, chills and some photophobia. No fever present. On 5/10/02, PT continues to experience significant body aches in arms, hips and elbows, other symptoms no longer present. PT is a veterinarian. The lot #'s of the first 4 doses are not available at this time.
Narrative: COVID infection following COVID vaccine series 12/17/2020, Pfizer, dose #1 01/07/2021, Pfizer, dose #2 09/01 pt cc: exposure: unknown 09/01 CXR impression: Stable cardiac and central pulmonary vascular enlargement without definite interstitial pulmonary edema. No compelling radiographic evidence for COVID pneumonitis. 09/01 COVID swab, result: detected 09/02 SARS-COV-2 IGG Eval: 1.92 09/02 FIBRINOGEN result: 638 09/02 DDIMER result: 0.28 09/02 clinically resolved
This spontaneous report was received from a Certified Medical Assistant (C.M.A) referring to an unspecified number of patients of unknown age and gender. The patients' pertinent medical history and concurrent conditions were not reported. On an unknown date, the patients were vaccinated with an improperly stored dose of VAQTA (strength, dose and route of administration were not provided) (lot # L015460 expiration date 20-JUL-2017 and L045713 expiry date 14-JAN-2017). The Certified Medical Assistant (C.M.A) stated that VAQTA was exposed to the following temperature conditions: -7 degrees C for 36 hours. There was not a previous temperature excursion. No adverse event was reported and no product quality issue was involved. This is one of several reports received from the same reporter. Additional information has been requested.
itching type of rash; Right below her neck she is have itching, irritation; Right below her neck she is have itching, irritation; This is a spontaneous report from a contactable consumer (patient's husband) reported for patient. A female patient of an unspecified age received dose 1 via an unspecified route of administration, administered in Arm Left on an unspecified date (Batch/Lot Number: Unknown) as SINGLE DOSE for covid-19 immunisation. The patient's medical history and concomitant medications were not reported.  The patient experienced itching type of rash (non-serious) on an unspecified date with outcome of unknown, right below her neck she is have itching, irritation (non-serious) on an unspecified date with outcome of unknown. Reporter stated, "My wife had like a reaction, like itching type of rash or something few weeks after the first Covid shot and I wanted to know what she can use to get rid of that itching? She had the shot on her left arm and right below her neck she is have itching, irritation."  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Severe head pain due to pituitary apoplexy with 20 mm hemorrhagic adenoma.  Admitted to hospital on 1/2/2022 for transsphenoidal  nasal endoscopic resection.  Discharged from hospital 1/13/2022.  Was on disability from work until 4/4/2022.  Ongoing lack pituitary function. Taking prescribed hydrocortisone and levothyroxine sodium.  Continue to have fatigue and muscle stiffness and pain. Vision is impaired in both eyes.
A serious report of urinary tract infection, constipation and tachycardia has been received from a study investigator concerning a 33-month-old female participating in a post-marketing study for FluMist. This case is submitted in accordance with MedImmune's post-marketing commitment on accelerated reporting for the newly indicated population of 2 years to 59 months of age for FluMist. The subject's medical history and concomitant medications were not reported. The subject received FluMist nasally, 0.25 ml per nostril, on 08-Oct-2009. The subject received one dose before the onset of the event. On 13-Nov-2009, the subject was admitted to the hospital for abdominal pain. In the morning of the admission day, she was in usual state of health and ate breakfast. Later, the subject did not eat as much as usual and then complained of abdominal pain around her belly button and preferred to be still and lie in a ball. On arrival in Emergency room, she was relaxed and lying with her legs extended. The subject was learning to potty-train and apparently held her urine because did not like to use toilet. She denied any fever, vomiting, diarrhea, runny nose, cough or other symptoms, but had tachycardia. She also had constipation and was admitted for observation. The subject was given glycerin suppository, and abdominal pain was resolved. She was also started on Cephalexin. On 14-Nov-2009, the subject was discharged from the hospital. The events of tract infections, constipation and tachycardia were resolved on 14-Nov-2009. The investigator assessed the causality for the events to FluMist as not related. The severity of the events was mild. Alternative etiology for the events was toilet training. The sponsor also assessed the causality for the events as not related to FluMist.
VOMITING, DEHYDRATION, AND HYPERGLYCEMIA. DECREASED INTAKE, HAD MUTIPLE EPISODES OF NON-BILOUS NON BLOODY VOMITING 4/26/19 RESULTED IN PATIENT HAVING INTESTINAL OBSTRUCTION INTUSSECPTION AND ABD INTESTINAL PERFORATION PATIENT NOW HAS OSTOMY.
Bad cough, bad cold symptoms night of Nov 24-25. Tested positive for Covid -19 on Nov. 25. Called Dr. office talked with doctor "on call". He interviewed me on phone and prescribed Paxlovid (reduced amount). Took Paxlovid Nov. 25 through Nov. 30. Felt better by Nov. 27. Tested positive on Nov. 28. Feel fine now on Dec. 2.
Flare of AIH/Recurrence of AutoimmuneHepatitisAfter COVID-19Vaccination; Flare of AIH/Recurrence of AutoimmuneHepatitisAfter COVID-19Vaccination; This is a literature report.  A 35-year-old female patient received COVID-19 Vaccine - Manufacturer Unknown, as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "autoimmune hepatitis" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: Covid-19 vaccine - manufacturer unknown (DOSE 1, SINGLE), for COVID-19 immunisation.  The following information was reported: AUTOIMMUNE HEPATITIS (medically significant), DISEASE RECURRENCE (medically significant), all with latency 14 days after the suspect product(s) administration, outcome "recovered" and all described as "Flare of AIH/Recurrence of AutoimmuneHepatitisAfter COVID-19Vaccination". The patient underwent the following laboratory tests and procedures: Biopsy: confirmed AIH 5 years ago; Blood immunoglobulin G: n/a; Hepatic enzyme: Elevation; aminotransferases: Increased; 4, notes: Probability : Non-probable; 6, notes: Probability : probable; Serology test: anti-smooth muscle antibody; Smooth muscle antibody: Elevation. Therapeutic measures were not taken as a result of autoimmune hepatitis, disease recurrence.; Sender's Comments: Based on the temporal relation, the association between the events of autoimmune hepatitis and disease recurrence and the suspect product cannot be completely ruled out. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.
arthralgia day p/vax;came to ER 2AM w/c/o SOB;tx w/inhaler;CPK nl;sed rate nl;no other info expected;
pt recv vax;later same day,arm became red & itchy at inject site;also warm & had devel a hard area at inject site;tx w/meds;
Pt went to doctors office 11-23-09 and baby no longer had heart beat. Fetus was delivered on 11-24-09. Mother was hospitalized from 11-24-09 to 11-26-09, an autopsy was performed on fetus. Blood work was done on mother.
Information has been received from a registered nurse concerning an 18 year old female with no known allergies who on 08/21/2001 was vaccinated with a first dose of hep b vaccine recombinant IM. Approximately twelve hours post vaccination on 08/22/2001, the pt developed a fever of 104 deg. F, general malaise, and aches. She went to the ER and was diagnosed with the flu. She was given IV fluids, antibiotics and a pain killer. According to the nurse, the pt felt sick for two more days and had a decreased appetite for one week. Subsequently, the pt recovered. No additional info is expected.
more fatigue; chills; fever; nausea; had a COVID rash on arm; This is a spontaneous report from a contactable consumer. A 32-year-old female consumer patient received a dose of BNT162B2 (PFIZER-BIONTEC COVID-19 mRNA VACCINE, Solution for injection, lot number and expiry date were not reported), via an unspecified route of administration, on Apr2021 (age at vaccination: 32 years), as dose number unknown, single dose for COVID-19 immunization. The patient's medical history included glucose intolerance and patient's concurrent condition included multiple sclerosis, spasms, low vitamin D and B, nerve pain, depression, migraines, fatigue, allergies, osteochondritis, bronchitis, pneumonia, strep throat, were ongoing from an unknown date. Patient's concomitant medication included oxybutynin, baclofen, colecalciferol(VITAMIN D), duloxetine hydrochloride(CYMBALTA), pregalin(LYRICA), methylphenidate hydrochloride(RITALIN), loratadine(CLARITIN), magnesium(MAGNESIUM), B MULTIVITAMIN, calcium(CALCIUM), were for unknown indication from an unknown date. On Apr2021, the patient experienced more fatigue, chills, fever, nausea, and had a COVID rash on arm. Outcome of the events was recovered on an unspecified date in 2021.  Follow-up activities closed. Batch/lot number not available for [Vaccine, BNT162B2].
Information has been received from a physician concerning a female (age unknown) who was vaccinated intramuscularly with a 0.5 mL dose of Pneumovax 23 (Lot #651356/0089F). On approximately 13-NOV-2006 ("within the last week") the patient developed redness and a rash from the shoulder to the elbow. The patient sought unspecified medical attention. At the time of this report, the outcome was unknown. No product quality complaint involved. Additional information has been requested.
Gotten it 8 times, vaccinated/suspected vaccination failure; shingles; lots of pain; I where my age is up where it is in the hip and the back it's a terrible pain; I where my age is up where it is in the hip and the back it's a terrible pain; Can barely move; bad blister; Extra dose administered; This case was reported by a consumer via interactive digital media and described the occurrence of suspected vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   Co-suspect products included Herpes zoster (Shingles vaccine) for prophylaxis and Herpes zoster (Shingles vaccine) for prophylaxis.   The patient's past medical history included operation nos (had operation on an unknown date) and shingles (had got shingles every year, got shingles 8 times).   On an unknown date, the patient received the 1st dose of Shingles vaccine, the 2nd dose of Shingles vaccine and the 3rd dose of Shingles vaccine. On an unknown date, less than 2 years after receiving Shingles vaccine and less than 9 months after receiving Shingles vaccine and Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant), shingles, pain, pain in hip, back pain, mobility decreased, blister and extra dose administered. On an unknown date, the outcome of the vaccination failure and extra dose administered were unknown and the outcome of the shingles, pain, pain in hip, back pain, mobility decreased and blister were not recovered/not resolved.   It was unknown if the reporter considered the vaccination failure, shingles, pain, pain in hip, back pain, mobility decreased and blister to be related to Shingles vaccine, Shingles vaccine and Shingles vaccine.  Additional details were provided as follows: The age at vaccination was not reported. The patient had got shingles every year, got shingles 8 times. The patient was vaccinated three times the first one a year ago and the current two ones 7 months ago after his/her operation, which led extra dose administered. Two weeks that the patient went through a rush and he/she still with a lot of pain and could barely move where his/her age was up where they was in the hip and the back it's a terrible pain and a very bad blister that was shingles and that was only cured with medicine from the physician or staying in the house a lot to everything they used in the hospital when they performed an operation on CD or there were some mistakes. But it was the microphone when one said the things sorry that hope that he/she could saw it was not that which he/she got operated on but when his/her friends more thanks was very good they disinfect for whoever wants to use it if they did not went to their physician. This case was considered as suspected vaccination failure as details regarding the laboratory test confirmation for shingles were unknown at the time of reporting. The follow-up could not be possible as no contact details were available.